Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Journal of Gastroenterology|June 23, 2010
Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectivesYing-Chun Shen, Chiun Hsu, Ann-Lii Cheng
Expert Review of Clinical Pharmacology|January 14, 2014
Sorafenib for the treatment of hepatocellular carcinoma across geographic regionsChiun Hsu, Ying-Chun Shen, Ann Lii Cheng
Journal of the Formosan Medical Association = Taiwan Yi Zhi|April 11, 2022
Immune checkpoint inhibitors for hepatocellular carcinoma - A game changer in treatment landscapeTsung-Hao Liu, Ying-Chun Shen, Ann-Lii Cheng
The Kaohsiung Journal of Medical Sciences|July 2, 2021
Evolution of systemic treatment for advanced hepatocellular carcinomaTsung-Che Wu, Ying-Chun Shen, Ann-Lii Cheng
Oncology|January 25, 2012
Targeting fibroblast growth factor receptor signaling in hepatocellular carcinomaAnn-Lii Cheng, Ying-Chun Shen, Andrew X Zhu
Oncology|May 5, 2012
A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regressionYing-Chun Shen, Chiun Hsu, Chia-Chi Cheng, et al.
Journal of Hepatocellular Carcinoma|August 11, 2016
Sorafenib in advanced hepatocellular carcinoma: current status and future perspectivesChih-Hung Hsu, Ying-Chun Shen, Yu-Yun Shao, et al.
Contemporary Clinical Trials|September 10, 2009
Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial designChiun Hsu, Ying-Chun Shen, Chia-Chi Cheng, et al.
Anti-Cancer Drugs|July 20, 2005
Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lungKun-Huei Yeh, Shiou-Hwei Yeh, Joeu-Pei Wan, et al.
Journal of Biomedical Science|August 21, 2025
CDK4/6 inhibitors synergize with radiotherapy to prime the tumor microenvironment and enhance the antitumor effect of anti-PD-L1 immunotherapy in triple-negative breast cancerWen-Chi Yang, Ming-Feng Wei, Ying-Chun Shen, et al.
Pageof 6